WST vs. RMD, BAX, SWAV, PODD, SOLV, TFX, PEN, DXCM, BSX, and BIIB
Should you be buying West Pharmaceutical Services stock or one of its competitors? The main competitors of West Pharmaceutical Services include ResMed (RMD), Baxter International (BAX), Shockwave Medical (SWAV), Insulet (PODD), NYSE:SOLV (SOLV), Teleflex (TFX), Penumbra (PEN), DexCom (DXCM), Boston Scientific (BSX), and Biogen (BIIB). These companies are all part of the "medical" sector.
ResMed (NYSE:RMD) and West Pharmaceutical Services (NYSE:WST) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.
ResMed received 150 more outperform votes than West Pharmaceutical Services when rated by MarketBeat users. However, 55.74% of users gave West Pharmaceutical Services an outperform vote while only 52.82% of users gave ResMed an outperform vote.
ResMed has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
ResMed has higher revenue and earnings than West Pharmaceutical Services. ResMed is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.
ResMed pays an annual dividend of $1.92 per share and has a dividend yield of 1.0%. West Pharmaceutical Services pays an annual dividend of $0.80 per share and has a dividend yield of 0.2%. ResMed pays out 31.7% of its earnings in the form of a dividend. West Pharmaceutical Services pays out 10.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 12 consecutive years and West Pharmaceutical Services has increased its dividend for 1 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
55.0% of ResMed shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 1.2% of ResMed shares are owned by insiders. Comparatively, 0.5% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, West Pharmaceutical Services had 6 more articles in the media than ResMed. MarketBeat recorded 20 mentions for West Pharmaceutical Services and 14 mentions for ResMed. West Pharmaceutical Services' average media sentiment score of 0.73 beat ResMed's score of 0.63 indicating that ResMed is being referred to more favorably in the media.
ResMed presently has a consensus target price of $199.20, indicating a potential upside of 8.18%. West Pharmaceutical Services has a consensus target price of $435.20, indicating a potential upside of 11.60%. Given ResMed's stronger consensus rating and higher probable upside, analysts clearly believe West Pharmaceutical Services is more favorable than ResMed.
West Pharmaceutical Services has a net margin of 20.12% compared to West Pharmaceutical Services' net margin of 19.77%. West Pharmaceutical Services' return on equity of 23.86% beat ResMed's return on equity.
Summary
West Pharmaceutical Services beats ResMed on 12 of the 21 factors compared between the two stocks.
Get West Pharmaceutical Services News Delivered to You Automatically
Sign up to receive the latest news and ratings for WST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
West Pharmaceutical Services Competitors List
Related Companies and Tools
